BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25516420)

  • 1. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
    Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
    Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
    Sengupta S; Sobo M; Lee K; Senthil Kumar S; White AR; Mender I; Fuller C; Chow LML; Fouladi M; Shay JW; Drissi R
    Mol Cancer Ther; 2018 Jul; 17(7):1504-1514. PubMed ID: 29654065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells.
    Mender I; Gryaznov S; Shay JW
    Oncoscience; 2015; 2(8):693-5. PubMed ID: 26425659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity.
    Mender I; Zhang A; Ren Z; Han C; Deng Y; Siteni S; Li H; Zhu J; Vemula A; Shay JW; Fu YX
    Cancer Cell; 2020 Sep; 38(3):400-411.e6. PubMed ID: 32619407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
    Zhang G; Wu LW; Mender I; Barzily-Rokni M; Hammond MR; Ope O; Cheng C; Vasilopoulos T; Randell S; Sadek N; Beroard A; Xiao M; Tian T; Tan J; Saeed U; Sugarman E; Krepler C; Brafford P; Sproesser K; Murugan S; Somasundaram R; Garman B; Wubbenhorst B; Woo J; Yin X; Liu Q; Frederick DT; Miao B; Xu W; Karakousis GC; Xu X; Schuchter LM; Mitchell TC; Kwong LN; Amaravadi RK; Lu Y; Boland GM; Wei Z; Nathanson K; Herbig U; Mills GB; Flaherty KT; Herlyn M; Shay JW
    Clin Cancer Res; 2018 Oct; 24(19):4771-4784. PubMed ID: 29563139
    [No Abstract]   [Full Text] [Related]  

  • 6. Turning telomerase into a Jekyll and Hyde case?
    Wellinger RJ
    Cancer Discov; 2015 Jan; 5(1):19-21. PubMed ID: 25583799
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Mender I; Batten K; Peyton M; Vemula A; Cornelius C; Girard L; Gao B; Minna JD; Shay JW
    Cancer Res; 2020 Mar; 80(5):929-936. PubMed ID: 31948943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short and dysfunctional telomeres protect from allergen-induced airway inflammation.
    Piñeiro-Hermida S; Martínez P; Blasco MA
    Aging Cell; 2021 May; 20(5):e13352. PubMed ID: 33942458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.
    Mender I; LaRanger R; Luitel K; Peyton M; Girard L; Lai TP; Batten K; Cornelius C; Dalvi MP; Ramirez M; Du W; Wu LF; Altschuler SJ; Brekken R; Martinez ED; Minna JD; Wright WE; Shay JW
    Neoplasia; 2018 Aug; 20(8):826-837. PubMed ID: 30015158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
    Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
    Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.
    Eglenen-Polat B; Kowash RR; Huang HC; Siteni S; Zhu M; Chen K; Bender ME; Mender I; Stastny V; Drapkin BJ; Raj P; Minna JD; Xu L; Shay JW; Akbay EA
    Nat Commun; 2024 Jan; 15(1):672. PubMed ID: 38253555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In perspective: An update on telomere targeting in cancer.
    Sugarman ET; Zhang G; Shay JW
    Mol Carcinog; 2019 Sep; 58(9):1581-1588. PubMed ID: 31062416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
    Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
    Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Super-telomeres in transformed human fibroblasts.
    Chiodi I; Belgiovine C; Zongaro S; Ricotti R; Horard B; Lossani A; Focher F; Gilson E; Giulotto E; Mondello C
    Biochim Biophys Acta; 2013 Aug; 1833(8):1885-93. PubMed ID: 23570868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 inhibitors block telomere elongation.
    Wang S; Pike AM; Lee SS; Strong MA; Connelly CJ; Greider CW
    Nucleic Acids Res; 2017 Aug; 45(14):8403-8410. PubMed ID: 28854735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of U-STELA for Accurate Measurement of Extremely Short Telomeres.
    Serakinci N; Cagsin H; Mavis M
    Methods Mol Biol; 2019; 2045():217-224. PubMed ID: 29542055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
    Babizhayev MA; Yegorov YE
    J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.
    Fischer-Mertens J; Otte F; Roderwieser A; Rosswog C; Kahlert Y; Werr L; Hellmann AM; Berding M; Chiu B; Bartenhagen C; Fischer M
    Cell Oncol (Dordr); 2022 Oct; 45(5):991-1003. PubMed ID: 35953764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells.
    Saretzki G; Ludwig A; von Zglinicki T; Runnebaum IB
    Cancer Gene Ther; 2001 Oct; 8(10):827-34. PubMed ID: 11687906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.